Moneycontrol PRO
UPCOMING EVENT:Moneycontrol Pro & Espresso (A Sharekhan Company) in association with Intrazon 2.0 bring to you India’s Largest Retail Intraday Traders Online Conference. Learn 12 Amazing Strategies from 12 Intraday Traders @ Rs. 600/-. Register Now!

EMA communication with regards to Trastuzumab does not mean an approval: Biocon

European Medicines Agency (EMA) has accepted the Trastuzumab application for review. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke at length about the same.

December 01, 2017 / 09:50 AM IST

European Medicines Agency (EMA) has accepted the Trastuzumab application for review. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke at length about the same.

Mazumdar Shaw said that EMA communication with regards to Trastuzumab does not mean an approval.

She further said that we had to withdraw our file and now we have resubmitted, which means that they have not accepted it for a review.

Talking about US approval, she said target action date for US Food and Drug Administration (US FDA) nod for Trastuzumab is December 3.

According to her, there are no technical issues with application with EMA for Trastuzumab.

Close
Watch accompanying video for more details.
CNBC-TV18
Tags: #Business
first published: Dec 1, 2017 09:50 am
Sections
ISO 27001 - BSI Assurance Mark